302941-54-4

Basic information

• Product Name: Pentanedioic acid, 2-isocyanato-, bis(phenylmethyl) ester, (2S)-
• CAS NO: 302941-54-4
• Molecular Formula: C20H19NO5
• Molecular Weight: 353.375
• Mol File: 302941-54-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Pentanedioic acid, 2-isocyanato-, bis(phenylmethyl) ester, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanedioic acid, 2-isocyanato-, bis(phenylmethyl) ester, (2S)-(302941-54-4)
• EPA Substance Registry System: Pentanedioic acid, 2-isocyanato-, bis(phenylmethyl) ester, (2S)-(302941-54-4)

Safety Data

• Hazardous Substances Data: 302941-54-4(Hazardous Substances Data)

Upstream product

• 75-44-5 phosgene 
• 4561-10-8 L-glutamic acid dibenzyl ester hydrochloride 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 2791-84-6 L-glutamic acid dibenzyl ester 4-toluenesulfonate 
• 2768-50-5 dibenzyl L-glutamate 

Downstream Products

• 404858-58-8 (S)-2-[3-((R)-1-Benzyloxycarbonyl-2-tert-butylsulfanyl-ethyl)-ureido]-pentanedioic acid dibenzyl ester 
• 681857-23-8 (S)-2-[3-[(S)-1-(benzyloxycarbonyl)-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]ureido]pentanedioic acid dibenzyl ester 
• 681857-46-5 (S)-2-[3-[(S)-α-(benzyloxycarbonyl)-4-hydroxybenzyl]ureido]pentanedioic acid dibenzyl ester 
• 681857-38-5 (S)-2-[3-[(S)-3-(benzyloxycarbonyl)-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]ureido]pentanedioic acid dibenzyl ester 
• 681857-48-7 (S)-2-[3-[(S)-1-(benzyloxycarbonyl)-2-(4-hydroxyphenyl)ethyl]ureido]pentanedioic acid dibenzyl ester 
• 404858-57-7 2-(3-tert-butyl-ureido)-pentanedioic acid dibenzyl ester 
• 16859-12-4 OC2 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.

Synthesis and biological evaluation of novel 10-substituted-7- Ethyl-10-hydroxycamptothecin (SN-38) prodrugs

In an attempt to improve the antitumor activity and reduce the side effects of irinotecan (2), novel prodrugs of SN-38 ( 3) were prepared by conjugating amino acids or dipeptides to the 10-hydroxyl group of SN-38 via a carbamate linkage. The synthesized compounds completely generated SN-38 in pH 7.4 buffer or in human plasma, while remaining stable under acidic conditions. All prodrug compounds demonstrated much greater in vitro antitumor activities against HeLa cells and SGC-7901 cells than irinotecan. The most active compounds, 5h, 7c, 7d, and 7f, exhibited IC50 values that were 1000 times lower against HeLa cells and 30 times lower against SGC-7901 cells than those of irinotecan, and the inhibitory activities of these prodrugs against acetylcholinesterase (AchE) were significantly reduced, with IC50 values more than 6.8 times greater than that of irinotecan. In addition, compound 5e exhibited the same level of tumor growth inhibitory activity as irinotecan (CPT-11) in a human colon xenograft model in vivo.

Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) [1]

-